A sodium tanshinone IIA sulfonate microsphere / hydrogel composite drug delivery system, its preparation method and application

The tanshinone IIA sodium sulfonate microsphere/hydrogel composite drug delivery system solves the problem of rapid drug loss, achieves in-situ fixation and slow release of the drug, significantly reduces the occurrence of postoperative peritoneal adhesions, and provides a safe and efficient treatment option.

CN122681791BActive Publication Date: 2026-11-17FOSHAN UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611183785.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-08-06
Publication Date
2026-11-17
Estimated Expiration
2046-08-06

AI Technical Summary

Technical Problem

Existing methods for treating postoperative peritoneal adhesions suffer from problems such as rapid drug loss, inability to achieve long-term fixation, and lack of sustained drug release. Traditional drug-loaded microspheres are difficult to achieve effective sustained drug release in the peritoneal cavity, and commonly used physical barrier materials lack bioactivity.

Method used

A tanshinone IIA sodium sulfonate microsphere/hydrogel composite drug delivery system was adopted. Gelatin microspheres loaded with tanshinone IIA sodium sulfonate were uniformly dispersed in the three-dimensional porous network of placental matrix hydrogel. The thermosensitive hydrogel formed a gel network at body temperature, thereby achieving in-situ fixation and sustained release of the drug.

Benefits of technology

Stable encapsulation and slow release of tanshinone IIA sodium sulfonate were achieved, significantly reducing adhesion levels and restoring the fibrinolytic system balance. This was significantly superior to using drug solutions or microsphere formulations alone, providing a safe and efficient in-situ immobilized drug delivery solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122681791B_ABST
    Figure CN122681791B_ABST
Patent Text Reader

Abstract

This invention belongs to the technical field of biomedical materials, specifically relating to a sodium tanshinone IIA sulfonate microsphere / hydrogel composite drug delivery system, its preparation method, and its application. STS is embedded in gelatin microspheres, which are then loaded into a thermosensitive amniotic extracellular matrix hydrogel. At low temperatures, it is an injectable liquid, while at body temperature it rapidly gels, achieving in-situ drug fixation and sustained release, exhibiting a dual sustained-release effect. In vivo pharmacokinetic studies in rats show that the composite system can prolong the half-life and improve bioavailability. In the prevention and treatment of postoperative abdominal adhesions, the composite system significantly reduces adhesion scores, superior to drugs or microspheres alone; at the molecular level, it can downregulate TGF-β, upregulate tPA, and downregulate PAI-1, restoring fibrinolytic balance and synergistically inhibiting fibrosis. Safety evaluation shows that its cell viability is >80% and hemolysis is negative. This invention's composite drug delivery system provides a safe and efficient in-situ fixation drug delivery scheme for the prevention and treatment of postoperative abdominal adhesions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the technical field of biomedical materials, specifically relating to a tanshinone IIA sodium sulfonate microsphere / hydrogel composite drug delivery system, its preparation method, and its application. Background Technology

[0002] Postoperative peritoneal adhesions are a highly prevalent complication after abdominal surgery. They not only affect the surgical outcome and can lead to a series of serious complications such as intestinal obstruction and female infertility, but also significantly reduce the patient's postoperative quality of life. Although various treatment methods are currently available in clinical practice, they have not yet achieved satisfactory results and remain a problem that needs to be addressed in surgical procedures.

[0003] Recent studies have shown that STS can regulate the progression of tissue fibrosis by inhibiting the activation of the TGF-β / Smad pathway, and can be used to prevent and treat the development of fibrosis in various organs, including the heart. Due to its downregulation of the TGF-β / Smad pathway in abdominal adhesions, STS has the potential to prevent and treat postoperative tissue adhesions.

[0004] However, current research on the formulation of STS (Synthetic Tissue Transfer) is still limited. While commonly used physical barrier materials in clinical practice (such as hyaluronic acid membranes and polylactic acid membranes) offer some anti-adhesion effects, they suffer from problems such as rapid in vivo degradation, lack of bioactivity, and inability to achieve sustained in-situ drug release. Furthermore, when traditional drug-loaded microspheres are administered intraperitoneally alone, they rapidly drift and are lost due to the continuous flow of peritoneal fluid, making it difficult to achieve long-term fixation at the lesion site and sustained drug release. Improving drug formulations to address these problems and enhance clinical efficacy has always been an important approach in new drug development. For example, changing injectable formulations to mucosal topical application can reduce the systemic risks associated with injections, reduce the dosage, and allow for sustained drug release over a longer period through formulation methods. Summary of the Invention

[0005] To address the aforementioned problems, the present invention aims to provide a tanshinone IIA sodium sulfonate microsphere / hydrogel composite drug delivery system, its preparation method, and its application.

[0006] The technical content of this invention is as follows: This invention provides a tanshinone IIA sodium sulfonate microsphere / hydrogel composite drug delivery system, comprising: Gelatin microspheres loaded with sodium tanshinone IIA sulfonate are composed of genipin-crosslinked gelatin and have sodium tanshinone IIA sulfonate embedded inside. And placental matrix hydrogel, which is thermosensitive, is liquid at below room temperature, and forms a three-dimensional porous gel network at body temperature; The gelatin microspheres loaded with sodium tanshinone IIA sulfonate are uniformly dispersed within the three-dimensional porous gel network of the placental matrix hydrogel. The average particle size of the drug-loaded gelatin microspheres is 10~500 μm, preferably 15~25 μm; The composite drug delivery system is in an injectable fluid state below room temperature. After gelling at body temperature, the release rate of the drug inside the drug-loaded gelatin microspheres is slowed down by the pore barrier effect of the three-dimensional porous gel network, thereby achieving a synergistic effect of in-situ fixation and sustained drug release. In the composite drug delivery system, the concentration of placental matrix hydrogel is 8~12 mg / mL; Preferably, the placental matrix hydrogel is a hydrogel prepared by digesting human amniotic membrane-derived decellularized extracellular matrix with pepsin. The placental matrix hydrogel contains endogenous collagen, elastin and sulfated glycosaminoglycans, and retains one or more bioactive molecules selected from placental growth factor (PlGF), vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8).

[0007] This invention also provides a method for preparing a sodium tanshinone IIA sulfonate microsphere / hydrogel composite drug delivery system, comprising the following steps: 1) Preparation of microspheres encapsulating sodium tanshinone IIA sulfonate (STS) 1.1) Preparation of the aqueous phase Tanshinone IIA sodium sulfonate (STS) was dissolved in water to prepare an STS aqueous solution, which was then mixed with gelatin to swell the gelatin. The mixture was then heated until dissolved to obtain a homogeneous STS-gelatin aqueous solution. The STS aqueous solution has a mass concentration of 1-20 mg / mL, preferably 5-10 mg / mL, and an encapsulation efficiency of >70% and a drug loading of >3% for STS. The gelatin concentration (w / v) in the STS-gelatin aqueous solution is 10%~20%, preferably 14%~18%; The mass-to-volume ratio of the gelatin to the STS aqueous solution is (0.1~5):(1~20) g / mL, preferably (0.5~2):(3~10) g / mL; The swelling time is 5-60 min, and the heating temperature is 40-80℃; 1.2) Preparation of the oil phase A hydrophobic oil phase is prepared by mixing a nonionic emulsifier with a low hydrophilic-lipophilic balance value (HLB≤6) and preheating it to the emulsification temperature. The hydrophobic oil phase includes one or more of liquid paraffin, vegetable oil, synthetic oil ester, silicone oil, and squalene, with liquid paraffin being preferred; The nonionic emulsifier includes one or more of sorbitan fatty acid esters, glycerol fatty acid esters, and polyglycerol fatty acid esters, preferably one or more of Span-80, Span-60, and Span-85; The volume percentage of nonionic emulsifier in the oil phase is 0.5% to 5%, preferably 1% to 3%; The preheating temperature is 40~80℃; 1.3) Emulsification and crosslinking Add the aqueous phase obtained in step 1.1) dropwise to the oil phase obtained in step 1.2), and emulsify under stirring conditions to form a water-in-oil emulsion; after emulsification, cool down, add genipin crosslinking agent solution, and pre-crosslink curing is carried out under low temperature conditions (ice bath), and then the temperature is raised to room temperature to continue curing; The volume ratio of the aqueous phase to the oil phase is 1:(4~10), preferably 1:(6~8). The emulsification stirring speed is 200~1500 rpm, and the emulsification time is 5~60 min; preferably 500~1000 rpm, 5~30 min; The cooling is to reduce the temperature to 0~15℃; The solvent of the genipin crosslinking agent solution is water, ethanol, or an aqueous ethanol solution, preferably an aqueous ethanol solution with a volume fraction of 30% to 90%; the mass concentration of the crosslinking agent solution is 0.5% to 10%, preferably 3% to 7%. The genipin crosslinking agent solution is added dropwise at a rate of 0.1–5 mL / min. The low-temperature pre-crosslinking time is 10~120 min, and the room temperature curing time is 2~48 h; 1.4) Post-processing After curing, a dehydrating agent is added to the system for dehydration, followed by solid-liquid separation. The oil phase is discarded, and the resulting microspheres are washed alternately with detergent and then dried to obtain gelatin microspheres encapsulated with STS (STS-GMS). The dehydrating agent includes one or more of anhydrous ethanol, isopropanol, acetone, and n-butanol, and its dosage is 0.5 to 5 times the total volume of the system, with a dehydration time of 5 to 60 minutes. The solid-liquid separation is performed by centrifugation or static sedimentation, with a centrifugation speed of 500~3000 rpm and a centrifugation time of 0.5~10 min; The volatile organic washing solvent is a combination of non-polar hydrocarbon solvent and polar alcohol solvent, wherein the non-polar hydrocarbon solvent includes one or more of petroleum ether, n-hexane, and cyclohexane, and the polar alcohol solvent includes anhydrous ethanol or isopropanol dehydrating agent, preferably a combination of petroleum ether and isopropanol, and the washing is performed alternately 2 to 6 times. 2) Preparation of composite drug delivery system The gelatin microspheres encapsulated with STS were mixed uniformly with a placental matrix hydrogel precursor solution at a temperature below the gelation temperature, so that the drug-loaded gelatin microspheres were uniformly suspended in the precursor solution, thus obtaining the drug-loaded composite system. The temperature below the gelation temperature is 0~15℃ (preferably ice bath conditions). The drug-loaded gelatin microspheres were suspended in a buffer solution before being mixed with the placental matrix hydrogel precursor solution; The mixing method is stirring or vortex oscillation; The placental matrix hydrogel precursor solution is prepared as follows: placental amniotic membrane tissue is decellularized to obtain decellularized placental matrix, which is sterilized by soaking in a double antibiotic solution and washed with PBS. The obtained decellularized placental matrix is ​​digested with pepsin under acidic conditions, and the pH is adjusted to neutral (6.5~7.5) to obtain placental matrix hydrogel precursor solution, which is kept below the gelation temperature for later use. The decellularization process includes: repeatedly freezing and thawing human placental tissue at -20°C 2-5 times, and repeatedly washing it in running water to mechanically detach the amniotic membrane from the placental tissue; sequentially treating the detached amniotic membrane tissue with trypsin-EDTA solution, Triton X-100 solution, and sodium deoxycholate solution by shaking to decellularize it, and washing with distilled water to remove residual reagents after each treatment; and freeze-drying the decellularized amniotic matrix to obtain the decellularized placental matrix. Preferably, the trypsin-EDTA solution has a mass concentration of 0.025%~0.1% and a mass concentration of 0.01%~0.05%; the Triton X-100 solution has a volume percentage concentration of 1%~5%; the sodium deoxycholate solution has a mass percentage concentration of 2%~6%; the treatment time for each reagent is independently 0.5~3 h, and the treatment temperature is 20~37℃. Preferably, the decellularized placental matrix is ​​freeze-dried and mechanically cut into small pieces of 0.5-5 mm before pepsin digestion, sterilized by soaking in 10,000 units of penicillin-antibody solution for 1 h, and rinsed three times with PBS for 5 min each time; the pepsin digestion conditions are: pepsin concentration of 0.5-2 mg / mL, digestion temperature of 20-37℃, and digestion time of 4-24 h; after digestion, alkali solution is added to neutralize hydrochloric acid to inactivate pepsin, and then phosphate buffer is added to adjust to isotonicity.

[0008] This invention also provides the application of the above-mentioned tanshinone IIA sulfonate sodium microsphere / hydrogel composite drug delivery system in the preparation of drugs for the prevention and / or treatment of abdominal adhesions after abdominal surgery; The composite drug delivery system is injected into the peritoneal cavity in liquid form via laparoscope or syringe, where it spontaneously forms a gel at body temperature, covering the surface of the peritoneal wound.

[0009] The beneficial effects of this invention are as follows: The present invention relates to a tanshinone IIA sodium sulfonate microsphere / hydrogel composite drug delivery system, in which STS is embedded in gelatin microspheres to solve the problems of rapid drug metabolism and instability. The drug-loaded microspheres are loaded into amniotic extracellular matrix (AM-ECM) hydrogel with rich biological activity and thermosensitive properties, thus constructing a tanshinone IIA sodium sulfonate microsphere / hydrogel composite drug delivery system (STS-GMS / AM-ECM) suitable for intraperitoneal administration. This achieves in-situ fixation and continuous release of the drug, while leveraging the physical barrier function of AM-ECM hydrogel, and is expected to produce better results in preventing and treating postoperative intraperitoneal adhesions.

[0010] In the preparation of the tanshinone IIA sodium sulfonate microsphere / hydrogel composite drug delivery system of the present invention, STS-GMS prepared by W / O emulsification crosslinking method allows STS to be stably embedded in gelatin microspheres in an amorphous form, which significantly improves the stability of the drug. Under normal storage conditions, the drug loading amount does not change significantly, and the microsphere morphology is well maintained. The results of cytotoxicity test show that STS-GMS has low cytotoxicity and good biocompatibility. This invention further utilizes placental amniotic membrane tissue as raw material to prepare AM-ECM hydrogel via a decellularization-enzymatic hydrolysis method. This hydrogel exhibits excellent thermosensitive properties, remaining as a liquid sol at low temperatures for easy injection, and rapidly solidifying at body temperature to achieve in-situ gelation within the peritoneal cavity. In vitro and in vivo degradation tests show that the hydrogel can gradually degrade in vivo, exhibiting a suitable in vivo retention time, which can meet the treatment needs during the critical period of postoperative adhesion prevention. Subcutaneous implantation and cytotoxicity tests confirm that the hydrogel only causes a mild and transient inflammatory response, without leading to tissue necrosis or degeneration, and is non-cytotoxic. The in vitro hemolysis test results are negative, and blood compatibility is good, indicating that the AM-ECM hydrogel possesses excellent biocompatibility.

[0011] This invention utilizes a physical mixing method to load STS-GMS into AM-ECM hydrogel, constructing an STS-GMS / AM-ECM composite drug delivery system. In this composite system, microspheres are uniformly dispersed within the hydrogel network and maintain their morphology. In vitro release studies demonstrate that the gel network of the AM-ECM hydrogel further delays the release of STS-GMS, achieving a dual sustained-release effect of "microsphere framework + gel barrier." In vivo pharmacokinetic studies in rats show that, compared to free drug, this composite system significantly reduces peak plasma concentration, prolongs half-life and mean residence time, and improves bioavailability, exhibiting long-acting circulating pharmacokinetic advantages. Regarding the prevention and treatment of postoperative peritoneal adhesions, the composite system significantly reduces adhesion grade scores, superior to administration of drug solutions or microsphere suspensions alone; histopathological examination shows intact mesothelial repair, indicating that this composite system effectively protects the peritoneal wound. At the molecular level, this composite system can significantly downregulate TGF-β expression while upregulating tPA and downregulating PAI-1, restoring the balance of the fibrinolytic system. It plays a synergistic role in preventing and treating adhesions by inhibiting the fibrosis process and activating fibrinolytic activity, and its effect is significantly better than using drug solutions or microsphere formulations alone.

[0012] The STS-GMS / AM-ECM of this invention has good sustained-release effects both in vivo and in vitro, and can effectively prevent postoperative peritoneal adhesions in rats, providing a safe and efficient in-situ fixed drug delivery solution for the prevention and treatment of postoperative adhesions in the abdominal cavity. Attached Figure Description

[0013] Figure 1 The effect of emulsifier concentration on drug loading and encapsulation efficiency, and microsphere morphology (400×) of STS-GMS; Figure 2 The effect of aqueous phase drug concentration on drug loading, encapsulation efficiency, and microsphere morphology (400×) of STS-GMS; Figure 3 The effect of the ratio of aqueous phase to oil phase on the drug loading, encapsulation efficiency, and microsphere morphology (400×) of STS-GMS; Figure 4 The effect of gelatin concentration on drug loading, encapsulation efficiency, and microsphere morphology (400×) of STS-GMS; Figure 5 The effect of crosslinking agent concentration on drug loading, encapsulation efficiency, and microsphere morphology (400×) of STS-GMS; Figure 6 The effect of emulsification stirring speed on drug loading, encapsulation efficiency, and microsphere morphology (400×); Figure 7 Three-dimensional surface and contour plot of the STS-GMS OD values ​​for each factor; Figure 8The image shows a microscope (400×) and particle size distribution diagram of an STS-GMS optical microscope. Figure 9 STS-GMS scanning electron microscope image; Figure 10 FT-IR plot; Figure 11 XRD pattern; Figure 12 The effect of temperature and light on the morphology of microspheres (400×). Figure 13 For gelatin microsphere cytotoxicity assay; Figure 14 The state of AM-ECM hydrogel at different temperatures and scanning electron microscope images of AM-ECM hydrogel; Figure 15 For AM-ECM hydrogel gelation kinetics; Figure 16 For AM-ECM hydrogel, in vitro weight change (A), in vitro degradation rate (B), and subcutaneous weight change (C) (n = 3); Figure 17 The appearance of AM-ECM hydrogel after subcutaneous injection in mice; Figure 18 HE staining results for subcutaneous injection of AM-ECM hydrogel; Figure 19 AM-ECM hydrogel cytotoxicity assay (A: L929 fibroblasts; B: relative cell viability of hydrogel extract). Figure 20 For AM-ECM hydrogel in vitro hemolysis test; Figure 21 The appearance and scanning electron microscope image of STS-GMS / AM-ECM (the dashed circle indicates STS-GMS). Figure 22 For STS-GMS / AM-ECM cytotoxicity assay; Figure 23 For in vitro release assays (n=3); Figure 24 The average score of adhesion grade in each group of rats (compared with the model group, *: P<0.05); Figure 25 Peritoneal adhesion status in rats of each group (A: blank group; B: model group; C: drug solution group; D: STS-GMS group; E: STS-GMS / AM-ECM group; dotted circles indicate adhesions between organs and abdominal wall, and yellow arrows indicate adhesion bands). Figure 26 HE staining results of rat adhesion tissue (AE is abdominal wall tissue; FJ is cecal wall tissue); Figure 27 The expression of inflammatory factors in rat serum; Figure 28 The expression of factors related to the fibrinolytic system in rat serum; Figure 29 The expression of TGF-β factor in rat serum; Note: Compared with the control group, a: P < 0.05; compared with the model group, b: P < 0.05; compared with the drug group, c: P < 0.05. Detailed Implementation

[0014] The present invention will be further described in detail below through specific implementation examples and accompanying drawings. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of protection of the present invention. After reading the present invention, any modifications of the present invention in various equivalent forms by those skilled in the art fall within the scope of the appended claims.

[0015] Unless otherwise specified, all raw materials and reagents used in this invention are from the conventional market.

[0016] Example 1 Preparation of gelatin microspheres encapsulating sodium tanshinone IIA sulfonate (STS-GMS) 1) Aqueous phase preparation: Take 0.8 g of gelatin, add 5 mL of the prepared 8 mg / mL STS aqueous solution to the gelatin and let it swell for 15 min. Then heat it at 50℃ to dissolve it into a homogeneous solution, which is the STS-gelatin aqueous phase solution. 2) Preparation of oil phase: Take 30 mL of liquid paraffin and add 0.6 mL of span-80 to prepare an oil phase containing 2% span-80, and keep it at 50℃. 3) Using a syringe, slowly add 5 mL of gelatin solution to the oil phase while stirring at 750 rpm, and continue emulsifying for 10 min to form a stable emulsion. Immediately transfer the solution to an ice-water bath and stir at a low stirring speed (500 rpm) for 15 min to lower the temperature. Then, slowly add 1 mL of 3% genipin (prepared with 70% ethanol) to the solution and allow it to crosslink and cure in an ice-water bath for 30 min. After that, transfer the solution to room temperature and continue curing for more than 12 h. 4) After the microspheres have completely solidified, add 20 mL of isopropanol to the suspension to dehydrate for 10 min, centrifuge at 1000 rpm for 1 min, discard the upper oil phase, and then wash three times alternately with petroleum ether and isopropanol. Finally, place the petroleum ether microsphere suspension in a fume hood to evaporate to dryness to obtain STS-GMS.

[0017] Using drug loading, encapsulation efficiency, and microsphere morphology as evaluation indicators, the preparation process of STS-GMS was optimized using a single-factor response surface methodology. The aim was to prepare STS-GMS with high drug loading and encapsulation efficiency and good microsphere morphology. The physicochemical properties of the microspheres prepared under the optimized process conditions were then evaluated, as follows: 1. Single-factor analysis The effects of emulsifier concentration (1%, 2%, 3%, 4%), aqueous phase drug concentration (4, 6, 8, 10 mg / mL), water-oil ratio (1:4, 1:6, 1:8, 1:10), gelatin concentration (12%, 14%, 16%, 18%, 20%), genipin concentration (1%, 3%, 5%, 7%), and emulsification stirring speed (600, 750, 900 rpm) on drug loading, encapsulation efficiency, and morphology of STS-GMS were investigated.

[0018] Results of emulsifier concentration study ( Figure 1 The results showed that as the emulsifier concentration increased, the drug loading and encapsulation efficiency decreased. Microspheres in the high concentration (3%) and 4% groups exhibited adhesion and poor sphericity. Although the 1% concentration group had higher drug loading and encapsulation efficiency, lumpy sediment and a small amount of microsphere adhesion appeared at the bottom of the gelatin emulsion during preparation, presumably due to instability caused by excessively low emulsifier concentration. Considering all factors, a 2% emulsifier was selected for subsequent experiments.

[0019] Results of aqueous phase drug concentration study ( Figure 2 The results showed that as the drug concentration increased, the drug loading gradually increased while the encapsulation efficiency gradually decreased; the increase in drug loading tended to level off when the drug concentration reached 10 mg / mL, and the encapsulation efficiency reached its lowest point; the microsphere morphology of all concentration groups was good, with no aggregation. The aqueous phase drug concentration had a significant impact on both drug loading and encapsulation efficiency, and was selected as a response surface optimization factor.

[0020] Results of water-oil ratio study ( Figure 3 The results showed that the drug loading and encapsulation efficiency first increased and then decreased with the increase of the oil phase ratio, and the microsphere morphology was good at all water-oil ratios. The water-oil ratio was selected as the response surface optimization factor.

[0021] Results of the study on gelatin concentration ( Figure 4 The results showed that the drug loading and encapsulation efficiency of the 12% concentration group were low, and the sphericity was poor. It is speculated that this was due to the loose structure of the microspheres after cross-linking caused by the low gelatin concentration and the loss of drugs during washing. The drug loading was the highest at the 14% concentration, the encapsulation efficiency tended to be stable, and the sphericity was better. Therefore, the concentration of gelatin in the aqueous phase was determined to be 14%.

[0022] Results of genipin concentration investigation ( Figure 5The results showed that drug loading and encapsulation efficiency increased significantly with increasing crosslinking agent concentration, but stopped increasing and even slightly decreased at 7%, presumably due to crosslinking saturation; the microspheres in all concentration groups showed good sphericity. Genipin concentration had a significant impact on both drug loading and encapsulation efficiency, and was selected as a response surface optimization factor.

[0023] Results of the investigation on emulsification stirring speed ( Figure 6 The results showed that different rotation speeds had no significant effect on drug loading and encapsulation efficiency; the microspheres in the 600 rpm group had slightly poorer sphericity, while the microspheres in the other groups had better morphology. The emulsification stirring speed was determined to be 750 rpm.

[0024] Based on the single-factor results, with emulsifier concentration fixed at 2%, gelatin concentration at 14%, and emulsification stirring speed at 750 rpm, the drug concentration in the aqueous phase (A), genipin concentration (B), and water-to-oil ratio (C) were selected as the factors for evaluation. A Box-Behnken response surface design was used for three-factor, three-level optimization (Table 1). Drug loading (Y1) and encapsulation efficiency (Y2) were used as response values. After normalization of each index using the Hassan method, the overall normalized value (OD value) was used as the criterion. The experimental arrangement and results of 15 groups are shown in Table 2. Binomial equation fitting was performed using Design Expert 8.0.6 software. The regression equation and variance analysis results are shown in Table 3. The correlation coefficient R of the fitted equation is... 2 =0.978, Corrected coefficient of determination R 2 Adj =0.938, indicating a good model fit; model P=0.0013 (P<0.05), which is statistically significant; the lack-of-fit term is not significant (P>0.05), indicating no lack of fit phenomenon. The order of influence of each factor on the OD value is B (genipin concentration) > A (aqueous phase drug concentration) > C (water-oil ratio), where A, B, AB, AC, BC, and A 2 B 2 All items were significant, and B was highly significant (P<0.001). The interaction effects of all factors were considered. Figure 7 The predicted optimal formulation and process conditions are: aqueous phase drug concentration 7.44 mg / mL, genipin concentration 4.04%, and water-oil ratio 1:8.

[0025] Table 1. Factors and levels in Box-Behnken response surface design

[0026] Table 2 Box-Behnken Experimental Design and Results Serial Number A B C <![CDATA[Y1]]> <![CDATA[Y2]]> OD 1 -1 -1 0 1.67 60.37 0 2 1 -1 0 2.31 42.95 0 3 -1 1 0 1.94 70.56 0.308 4 1 1 0 3.87 71.43 0.887 5 -1 0 -1 2.18 77.65 0.471 6 1 0 -1 2.79 51.66 0.350 7 -1 0 1 1.88 68.45 0.262 8 1 0 1 3.76 69.88 0.840 9 0 -1 -1 2.07 50.28 0.193 10 0 1 -1 3.24 79.16 0.846 11 0 -1 1 2.51 61.33 0.442 12 0 1 1 2.81 68.65 0.607 13 0 0 0 3.11 75.82 0.770 14 0 0 0 3.19 77.73 0.816 15 0 0 0 3.12 75.91 0.775 Table 3 Results of Response Surface Analysis of Variance

[0027] 2. Optimal process verification Three batches of STS-GMS were prepared repeatedly according to the optimal process. Encapsulation efficiency and drug loading were determined using an enzymatic method: 20 mg of STS-GMS was accurately weighed and added to 10 mL of 0.075% trypsin solution (prepared with pH 7.4 PBS). The microspheres were completely degraded by shaking at 37℃ and 100 rpm for 2 h. After dilution, the STS content was determined under the following chromatographic conditions (column: ACE super C18 column, 4.6 mm × 250 mm, 5 μm; mobile phase: 0.2% dipotassium hydrogen phosphate (pH=3)-methanol (20:80); detection wavelength: 271 nm; flow rate: 1.0 mL / min; injection volume: 20 μL). The drug loading and encapsulation efficiency were calculated. The measured drug loading was 3.78 ± 0.028%, and the encapsulation efficiency was 74.93 ± 0.57%, which were close to the predicted values, indicating good predictive ability of the model.

[0028] Drug-loaded microspheres and blank microspheres were prepared according to the optimized formulation and process, and their physicochemical properties were evaluated by STS-GMS. 1. Physicochemical characterization of STS-GMS Microscopic morphology observation and particle size determination Figure 8 The scanned electron microscope (SEM) showed that the blank microspheres were blue-green, while the drug-loaded microspheres were purplish-red, and both exhibited good sphericity. The particle size distribution was normal, with a median diameter of 18.41 ± 0.38 μm, and the distribution was uniform. Figure 9 The microspheres are round, with a smooth and dense surface and no cracks.

[0029] FT-IR analysis ( Figure 10 The data shows that STS active pharmaceutical ingredient (A) is 3500 cm³. -1 The vibration at this point should be an O-Na stretching vibration, 1674 cm. -1 The strong absorption peak is due to the stretching vibration of -C=O, at 1218 cm⁻¹. -1 The strong absorption characteristic peak that appears is in the stretching vibration region of -SO, at 655 cm⁻¹. -1 The absorption peak should be the out-of-plane bending vibration peak of CH on the aromatic ring of STS. The C-curve still shows the -SO stretching vibration peak and "fingerprint" pattern of STS, while the infrared spectrum of drug-loaded microspheres hardly shows any characteristic peaks of STS, indicating that STS has been encapsulated in gelatin microspheres.

[0030] XRD analysis ( Figure 11The X-ray diffraction patterns show that STS exhibits distinct crystalline diffraction peaks in the 10–80° range, indicating that STS exists in a crystalline form. Blank microspheres show no obvious diffraction peaks in this range, suggesting that the blank microspheres exist in an amorphous, non-crystalline form. However, the X-ray diffraction patterns of the physical mixture still show STS crystalline diffraction peaks, indicating that STS still exists in a crystalline form. In the drug-loaded microspheres, the crystalline diffraction peaks of STS disappear, indicating that STS is embedded within the gelatin microspheres and exists in an amorphous, non-crystalline state within the microspheres.

[0031] 2. Stability Study of STS-GMS The STS-GMS samples prepared above were placed at 4℃, 25℃, and 40℃ for 10 days (to investigate the effect of temperature), and at 25℃ under 4500±500 Lx light for 10 days (to investigate the effect of light). Samples were taken at 0, 5, and 10 days to determine the drug loading and observe the morphology. The rate of change was calculated with the drug loading at 0 days as 100%. Results (Table 4) Figure 12 The results showed that: at 4℃ and 25℃, there was no significant change in drug loading, the microspheres maintained good morphology, and there was no aggregation; at 40℃, the drug loading changed slightly more but was acceptable, and the morphology remained unchanged; under light conditions, the drug loading decreased slightly, but the morphology remained unchanged. This indicates that STS-GMS is stable at room temperature and lower temperatures.

[0032] Table 4. Effects of temperature and light on drug loading in STS-GMS 0 d 5 d 10 d 4℃ 100% 100.24% 99.74% 25℃ 100% 99.58% 100.32% 40℃ 100% 97.15 97.67% illumination 100% 99.61% 97.82% 3. Cytotoxicity test of gelatin microspheres To investigate the biocompatibility of the prepared gelatin microspheres, L929 fibroblasts were used as a model cell to evaluate their biocompatibility. Blank microspheres were sterilized by immersion in 75% ethanol for 30 min, washed three times with PBS, and then cultured in DMEM medium containing 10% fetal bovine serum at concentrations of 0.8, 0.4, 0.2, 0.1, and 0.05 mg / mL, and incubated at 37°C for 24 h. L929 cells were cultured at 5 × 10⁶ cells per well. 3 Cells were seeded in 96-well plates and cultured for 24 h. Then, 100 μL of different concentrations of microsphere cell culture medium were added to each well (normal medium was used as a control, and each group had 6 replicates). After culturing for another 24 h or 48 h, 100 μL of DMEM medium containing 10% CCK-8 was added and incubated for 1 h. The OD value was measured at 450 nm and the relative cell viability was calculated.

[0033] The results are visible. Figure 13The relative cell viability values ​​of the microsphere cell culture medium groups with different concentrations were all above 80% after co-culturing at two time periods (24 h and 48 h), indicating that the gelatin microsphere material has no cytotoxicity, good biocompatibility, and is suitable for use as a drug carrier.

[0034] STS (sulfonic acid glycosides) are highly polar, making them difficult to penetrate biological membranes and easily metabolized in the body, resulting in poor efficacy. Furthermore, due to their sulfonic acid groups, local administration of the solution into the peritoneum may cause significant irritation to the peritoneum, leading to patient discomfort. Gelatin, a natural polymer derived from animal collagen, possesses excellent physicochemical properties, biocompatibility, and biodegradability, making it an ideal carrier material for microsphere preparation. Using gelatin microspheres as a drug delivery system for STS will help improve drug stability, reduce peritoneal irritation, and allow for slow, controlled release of STS, thus achieving a longer therapeutic effect and improving bioavailability.

[0035] Example 2 Preparation of AM-ECM hydrogels 1) Mechanical stripping and decellularization of human placental amniotic tissue a) Fresh human placental tissue was placed at -20℃ and repeatedly frozen and thawed 3 times, and washed repeatedly in running water 3 times, each time for 20 minutes, so that the amniotic membrane tissue was mechanically peeled out from the fresh placenta. b) The amniotic membrane tissue was decellularized sequentially using the prepared 0.05% trypsin-EDTA solution, 3% Triton X-100 solution and 4% sodium deoxycholate solution. The amniotic membrane tissue was decellularized by shaking for 1 h (25℃, 100 rpm) with each reagent. Before changing to the next solvent, the amniotic membrane tissue was repeatedly washed with distilled water to remove residual reagents. c) Freeze-dry the decellularized amniotic matrix at -50°C for 24 h, and store the dried sample at -20°C or proceed to the next step of the experiment; 2) Enzymatic hydrolysis of decellularized amnion Under aseptic conditions, the dried amniotic membrane matrix, after decellularization, was mechanically cut into small pieces of approximately 1×1 mm. These pieces were then soaked in 10,000 units of penicillin-antibiotic solution for 1 hour for sterilization, followed by rinsing three times with PBS solution for 5 minutes each time, to obtain the decellularized placental matrix. The matrix was then transferred to a reaction flask, and under aseptic conditions, a certain amount of 1 mg / mL acidic pepsin solution (containing 0.01 mol / L HCl, pH = 2) was added. The mixture was stirred continuously at 25°C for 4–12 hours until the matrix was completely degraded. One-tenth of the volume of 0.1 mol / L NaOH solution was added to the degradation product to neutralize the hydrochloric acid and inactivate the pepsin, thus terminating the reaction. One-ninth of the volume of 10×PBS solution was added to the neutralized degradation product to provide isotonic conditions. The resulting product was the AM-ECM hydrogel.

[0036] The gelation kinetics and microstructure of AM-ECM hydrogel were characterized, and its in vivo and in vitro degradation, biocompatibility and blood compatibility were further studied, in order to prepare a thermosensitive hydrogel with good biocompatibility and appropriate retention time in vivo for continuous intraperitoneal drug delivery.

[0037] 1. Scanning electron microscopy observation of AM-ECM hydrogel structure The AM-ECM hydrogel prepared above was incubated at 37°C for 30 min to trigger its gelation. The gelled hydrogel was fixed overnight at 4°C in an electron microscopy fixative containing 2.5% glutaraldehyde, dehydrated by ethanol gradient, transferred to a critical point dryer for drying, and then sputtered with gold for about 30 s on an ion sputtering stage. The sample was then observed and imaged under a scanning electron microscope.

[0038] like Figure 14 As shown, the enzymatically hydrolyzed hydrogel is milky white and transparent, exhibiting a viscous liquid state at 4°C and polymerizing into a jelly-like solid at 37°C. Scanning electron microscopy images reveal that the polymerized AM-ECM hydrogel has an interwoven filamentous structure with a relatively loose internal structure.

[0039] 2. Gelation kinetics a) Investigation of AM-ECM hydrogel gelation kinetics at different temperatures The gelation kinetics were investigated using a turbidimetric method. A 10 mg / mL hydrogel was placed at 4℃ and 37℃, and the absorbance was measured at 490 nm every 1 min, then every 2 min after 6 min, for a total of 20 min.

[0040] b) Investigation of gelation kinetics of AM-ECM hydrogels with different matrix concentrations The gelation kinetics of hydrogels with different matrix concentrations (6, 8, 10 mg / mL) were investigated at 37℃. Data are expressed as NA = (A - A0) / (Amax -A0) Normalization processing, where A is the absorbance value at different time points, A max A is the maximum absorbance value in the obtained data, and A0 is the absorbance value at 0 min.

[0041] The results are as follows Figure 15 As shown, at 4℃, the absorbance of the AM-ECM hydrogel was low (0.758) and showed no significant change. However, at 37℃, its absorbance jumped sharply to a high level (2.779) after 2 minutes, and then remained relatively stable. This indicates that the hydrogel does not undergo gelation assembly at 4℃, but can complete gelation assembly in a shorter time at 37℃, exhibiting a certain degree of temperature sensitivity. Furthermore, AM-ECM hydrogels of different concentrations could all rapidly complete gelation assembly at 37℃. The normalized absorbance of the 6 mg / mL and 8 mg / mL matrix concentrations was 0.89 at 3 minutes, and still showed a slow upward trend. The 10 mg / mL matrix concentration hydrogel showed a shorter gelation equilibrium time at 37℃ (normalized absorbance reached 0.97 at 3 minutes). Unless otherwise specified, the matrix concentration of AM-ECM hydrogels in subsequent experiments was 10 mg / mL.

[0042] 3. In vitro and in vivo degradation test of AM-ECM hydrogel a) In vitro degradation Two mL of 10 mg / mL hydrogel (n=3) was gelled at 37℃ and weighed (m0). The gel was placed in 50 mL of pH 7.4 PBS and shaken at 37℃ and 100 rpm. The gel was weighed and the PBS was replaced every 1 day. The degradation rate was calculated as (DR, %) = (m0-m)×100% / m0, where m0 is the initial mass of the gel and m is the mass of the gel taken at different time points.

[0043] Depend on Figure 16 It was found that the hydrogel continuously degraded in PBS solution at pH 7.4. The hydrogel degraded rapidly in the early stages, reaching 46.55±5.84% degradation by day 7. The degradation rate gradually slowed down in the later stages, reaching only 61.89±8.34% by day 14. Furthermore, the degradation of the subcutaneous hydrogel in mice was similar to that in vitro. At day 0, the weight of the AM-ECM hydrogel was 0.598±0.047 g, while at day 3 it was only 0.337±0.040 g, showing a significant decrease and rapid degradation. The degradation gradually slowed down in the later stages, reaching 0.204±0.050 g by day 14.

[0044] b) Subcutaneous lysis 1 mL of 10 mg / mL AM-ECM hydrogel was subcutaneously injected into the back of mice. Three mice were sacrificed on days 3, 5, 7, and 14, and the size of the AM-ECM hydrogel and the condition of the surrounding tissue were photographed and recorded. The residual hydrogel under the skin was carefully removed, weighed, and the weight was recorded.

[0045] like Figure 17 As shown, the AM-ECM hydrogel remains fixed in situ at the injection site after subcutaneous injection, and its volume gradually decreases over time. On day 14, the volume of the AM-ECM hydrogel has decreased significantly, but its overall morphology remains relatively intact. Throughout the experiment, no mice experienced death, poisoning, or intestinal obstruction. This indicates that the hydrogel has suitable in vivo retention properties, meeting the treatment needs during the critical period of postoperative adhesion prevention.

[0046] 4. In vitro and in vivo biocompatibility tests of AM-ECM hydrogel a) Tissue inflammatory response after subcutaneous AM-ECM hydrogel implantation As in the previous experiment, three mice were sacrificed at 3, 5, 7, and 14 days, and the gel and surrounding tissue were collected, fixed, paraffin-embedded, and stained with hematoxylin and eosin (HE). Results are shown below. Figure 18 The AM-ECM hydrogel had a relatively clear boundary with the surrounding tissue. On the day of injection, there was no inflammatory cell infiltration in the hydrogel and its surrounding tissue. On days 3 and 5, a certain amount of neutrophil and macrophage proliferation was observed at the junction of the hydrogel and the tissue, resulting in inflammatory infiltration. However, on days 7 and 14, the inflammatory cell infiltration gradually decreased, indicating that the hydrogel may cause a relatively mild acute inflammatory response. However, the inflammatory response gradually weakened over time, and no obvious tissue necrosis or degeneration was observed in the surrounding tissue.

[0047] No bleeding, congestion, necrosis, or edema was observed at the injection site in the mice during the entire experiment. Therefore, the inflammatory response induced by AM-ECM hydrogel was only a temporary foreign body rejection reaction, indicating that the hydrogel has good biocompatibility and can be further applied in vivo.

[0048] b) In vitro cytotoxicity assay of AM-ECM hydrogel Using L929 fibroblasts as model cells, a 100% extract was prepared by immersing the hydrogel at a ratio of 1:10 (v / v) in DMEM containing 10% fetal bovine serum and 1% penicillin antibody for 24 h. The extract was then diluted to 50%, 25%, and 12.5%, and measured using the CCK-8 assay as described in Example 1.

[0049] Depend on Figure 19The results showed that the relative cell viability of the different concentrations of hydrogel extracts after co-culturing at two time periods (24 h and 48 h) was all above 80%, indicating that AM-ECM hydrogels have no cytotoxicity and further demonstrating their good biocompatibility, making them suitable as drug carriers.

[0050] 5. AM-ECM hydrogel in vitro hemolysis test Since the gel material of this invention is a medical material used to prevent and treat postoperative peritoneal adhesions, it will come into direct contact with the damaged wound in the abdominal cavity and may come into contact with blood. Therefore, it is necessary to examine the blood compatibility of the material through an in vitro hemolysis test.

[0051] Collect 5 mL of fresh rabbit marginal ear vein blood (anticoagulated with sodium heparin), centrifuge at 3000 rpm for 5 min, discard the supernatant plasma, wash with 0.9% NaCl until the supernatant is colorless and transparent, and prepare a 2% erythrocyte suspension. Add 10 mg / mL hydrogel to 0.9% NaCl at a ratio of 1:10 (v / v) and incubate at 37℃ for 24 h to prepare the test solution. Perform the hemolysis test according to the method in Table 5 (add 1.0, 1.5, 2.0, and 2.5 mL of test solution to test tubes 1-4 respectively; do not add test solution to negative control tubes; add 2.5 mL of distilled water to positive control tubes), and observe after incubating at 37℃ for 1 h.

[0052] Table 5 In vitro hemolysis test method serial number 1 2 3 4 5 6 2% red blood cell suspension (mL) 2.5 2.5 2.5 2.5 2.5 2.5 0.9% NaCl solution (mL) 1.5 1 0.5 0 2.5 0 Test solution (mL) 1 1.5 2 2.5 0 0 Distilled water (mL) 0 0 0 0 0 2.5 Depend on Figure 20 As can be seen, the positive control tube (No. 6) was clear red with no cell residue at the bottom, indicating hemolysis; the test tubes (Nos. 1-4) and the negative control tube (No. 5) had clear, colorless supernatants with red blood cell precipitation, but no hemolysis. This shows that AM-ECM hydrogel does not cause hemolysis in wounds and meets the requirements for medical materials.

[0053] The preparation of the placental matrix hydrogel (AM-ECM hydrogel) in this application is based on the inventor's published paper "Human amnion extracellular matrix derived bioactive hydrogel for cell delivery and tissue engineering", which discloses its use in three-dimensional stem cell culture and tissue engineering repair, focusing only on the use of the hydrogel itself as a cell scaffold.

[0054] Example 3 Preparation of a Tanshinone IIA Sulfonate Sodium Microsphere Hydrogel Composite Drug Delivery System The STS-GMS prepared in Example 1 was weighed, suspended in PBS solution, and then added to the AM-ECM hydrogel prepared in Example 2. The mixture was continuously stirred and dispersed evenly to prepare a tanshinone IIA sodium sulfonate microsphere hydrogel composite drug delivery system with a gel matrix concentration of 10 mg / mL, namely STS-GMS / AM-ECM.

[0055] The relevant properties of STS-GMS / AM-ECM are characterized as follows: 1. STS-GMS / AM-ECM structure observed by scanning electron microscopy Same as AM-ECM electron microscopy scanning processing, by Figure 21 As can be seen, the hydrogel loaded with microspheres is purplish-red. Similar to the blank hydrogel without microspheres, it is a viscous liquid at 4°C and can polymerize into a jelly-like solid at 37°C. Scanning electron microscopy images show that the polymerized microsphere-loaded hydrogel has STS-GMS embedded in its interwoven filamentous structure; the shape and structure of the microspheres are not damaged, and the sphericity is good.

[0056] 2. In vitro cytotoxicity study of STS-GMS / AM-ECM Using L929 cells as a model, 100%, 50%, 25%, and 12.5% ​​extracts of the blank composite system (blank microspheres + hydrogel) were prepared and measured by the CCK-8 method.

[0057] The results of the STS-GMS / AM-ECM in vitro cytotoxicity assay are shown... Figure 22 The results show that the relative cell viability values ​​of different concentrations of cell culture medium after co-culturing at two time periods (24 h and 48 h) were all above 80%, indicating that the introduction of gelatin microspheres does not affect the biocompatibility of AM-ECM hydrogel, and the materials of the composite drug delivery system have good biocompatibility.

[0058] 3. Dynamic dialysis method was used to investigate the in vitro release performance of STS-GMS / AM-ECM. The in vitro release behavior of STS active pharmaceutical ingredient (API), STS-GMS, and STS-GMS / AM-ECM was investigated using dynamic dialysis with pH 7.4 PBS as the release medium. For the API and STS-GMS groups: 5 mg of STS API or an equivalent amount of STS-GMS was accurately weighed, suspended in PBS, and transferred to a dialysis bag. For the STS-GMS / AM-ECM group: an equivalent amount of the composite system was accurately transferred, incubated at 37°C for 10 min to allow gel solidification, and then transferred to a dialysis bag. Each dialysis bag was placed in 100 mL of PBS and shaken at 37°C and 100 rpm. Samples of 5 mL were taken at 0.5, 1, 2, 4, 8, 12, and 24 h, and the PBS was replenished to determine the drug concentration. The cumulative in vitro release percentage (Q, %) for each group was calculated using the following formula, and in vitro release curves were plotted using Origin 9.0 software.

[0059] Q=[C n ×V1+(C1+C2+……+C n-1 [100 / W] × V² × 100; C n V1 is the sample concentration at the nth sampling, V2 is the release medium volume (100 mL), V3 is the sampling volume (5 mL), C4 is the sample concentration at the first sampling, and C5 is the sample concentration at the nth sampling. n-1 Similarly, W represents the total amount of STS in the dialysis bag.

[0060] STS-GMS / AM-ECM in vitro release results are as follows: Figure 23 As shown in the figure, both STS-GMS / AM-ECM and STS-GMS have good sustained-release effects. At 8 h, the STS API group had released 99.50±1.30%, while the STS-GMS group and STS-GMS / AM-ECM group released 44.21±3.34% and 30.49±2.11%, respectively. By 24 h, the STS-GMS group and STS-GMS / AM-ECM group had released 61.07±3.31% and 52.06±1.22%, respectively. The release curves of the two formulations were statistically different from those of the STS API group (P<0.05). Furthermore, there was a statistically significant difference in the cumulative release percentage between STS-GMS and STS-GMS / AM-ECM (P < 0.05), indicating that AM-ECM hydrogel also has a certain sustained-release effect in the in vitro release model. Combining it with STS-GMS can achieve a dual sustained-release effect, making the microsphere-loaded hydrogel better at delaying drug release compared to the simple microsphere suspension.

[0061] The in vitro release curve fitting results of STS-GMS and STS-GMS / AM-ECM are shown in Table 6. Both STS-GMS and STS-GMS / AM-ECM best fit the first-order release model. The equation for STS-GMS is Q = 62.0257 × (1 - e -0.15775t ), R 2 The value is 0.9991; the equation for STS-GMS / AM-ECM is Q = 56.9487 × (1 - e -0.0988t ), R 2 It is 0.9970.

[0062] Table 6. Fitting of STS-GMS and STS-GMS / AM-ECM in vitro release models STS-GMS STS-GMS / AM-ECM Level 0 <![CDATA[Q=14.0319+2.3403t(R 2 =0.7931)]]> <![CDATA[Q=7.9741+2.0556t(R 2 =0.9072)]]> Level 1 <![CDATA[Q=62.0257×(1-e -0.15775t )(R 2 =0.9991)]]> <![CDATA[Q=56.9487×(1-e -0.0988t )(R 2 =0.9970)]]> Higuchi equation <![CDATA[Q=14.1446t 1 / 2 -1.7126(R 2 =0.9473)]]> <![CDATA[Q=11.99857t 1 / 2 -4.86404(R 2 =0.9930)]]> Riger-Peppas equations <![CDATA[Q=11.6203t 0.5575 (R 2 =0.9487)]]> <![CDATA[Q=7.2599t 0.6299 (R 2 =0.9887)]]>

[0063] Experimental Example 1 An experiment using STS-GMS / AM-ECM to prevent postoperative peritoneal adhesions in rats. 1. Establishment of a rat model of postoperative peritoneal adhesion. A rat model of postoperative abdominal adhesions was established using a physical injury method combining cecal scraping and abdominal wall clamping. After anesthetizing SD rats with 10% chloral hydrate, the abdomen was incised approximately 2 cm along the linea alba. The cecum was located and repeatedly scraped with a scalpel until the cecal wall became congested and swollen with scattered punctate bleeding points. A small amount of 75% ethanol was added, and the rats were returned to their original position. Hemostatic forceps were used to repeatedly clamp the abdominal walls on both sides of the incision at the maximum clamping position and perform appropriate scraping. The wound was then sutured. Seven days post-surgery, the rats were laparotomized to observe the adhesions. Throughout the entire procedure, the rats were placed on a 37°C constant-temperature heating plate, and strict aseptic technique was adhered to. The surgical time was controlled within 20 minutes.

[0064] The anesthetic wore off 6-8 hours post-surgery, and the rats gradually awoke, but were extremely weak. For the first 24 hours post-surgery, the rats were largely inactive, drinking only small amounts of water and food. By day 3 post-surgery, all groups of rats had largely recovered, exhibiting high mobility and good wound healing. By day 7 post-surgery, the wounds were mostly healed, and the rats in all groups were drinking and eating normally. Throughout the experiment, most rats showed good healing without infection, indicating that the modeling surgery was relatively successful.

[0065] Within 7 days post-surgery, the food intake of rats in the control group remained relatively stable, and their defecation was normal. Compared with the control group, the basic food intake of rats in the other groups decreased, with the model group having less defecation, mostly loose stools from 0 to 3 days post-surgery, and slightly lower activity sensitivity compared to other groups.

[0066] 2. Animal grouping and intervention methods Forty male SD rats were randomly divided into 5 groups (n=8 per group). For the first 12 hours of the experiment, the rats were fasted but not deprived of water. The treatments for each group were as follows: 1) Blank group: No surgical modeling was performed after laparotomy, and normal saline was instilled before laparotomy closure; 2) Model group: After laparotomy, the model was created, and physiological saline was instilled before laparotomy was closed; 3) Drug solution group: After abdominal surgery, STS solution was instilled before abdominal closure, and the dosage was 10 mg / kg. 4) STS-GMS group: After laparotomy, the model was established, and STS-GMS suspension was instilled before laparotomy was closed. The dosage was 10 mg / kg. 5) STS-GMS / AM-ECM group: After laparotomy, the model was created, and before laparotomy, AM-ECM hydrogel loaded with microspheres was infused at a dose of 10 mg / kg.

[0067] 3. Adhesion Level Scoring Method The degree of peritoneal adhesion in rats was evaluated using a gross adhesion grading method. The degree of peritoneal adhesion was comprehensively evaluated from three aspects: the number of adhesion bands, the tensile strength of the adhesion bands, and the degree of adhesion. The specific scoring method is shown in Tables 7, 8, and 9.

[0068] Table 7 Scoring Criteria for the Number of Adhesions grade Number of adhesive strips score Level 0 0 0 Level I 1 1 Level II 2 2 Level III 3 3 Level IV Three or more, or organs completely adhered to the abdominal wall 4 Table 8 Scoring Criteria for Tensile Strength of Adhesive Bands grade Tensile strength score Level 0 Non-adhesive band 0 Level I slight thin-film separation 1 Level II Passive separation 2 Level III sharp separation 3 Table 9. Scoring Criteria for Adhesion Degree grade Adhesion degree score Level 0 Non-adhesive band 0 Level I Thin film adhesive band 1 Level II Vascularized adhesions 2 Level III Dark or sticky adhesive bands 3 The results of the rat adhesion grade scoring are shown in Table 10. Figure 24 The results showed that none of the rats in the model group had a score of 0 in any of the three aspects of adhesion, indicating that all rats developed peritoneal adhesions. The scores for the number of adhesion bands were mostly between 2 and 4, the tensile strength between 2 and 3, and the degree of adhesion between 1 and 2. The average adhesion score in the model group was 6.63, indicating that this method could successfully establish a rat postoperative adhesion model. The average adhesion scores in the drug solution group and the STS-GMS group were 5.88 and 4.88, respectively. While the adhesion scores in both groups were slightly lower than those in the model group, there was no significant difference (P > 0.05), suggesting that the drug solution and STS-GMS groups could prevent postoperative peritoneal adhesions in rats to some extent, but the effect was not significant. In the STS-GMS / AM-ECM group, the scores for the number of adhesions and tensile strength were concentrated in the range of 0-2, while the score for adhesion degree was mostly concentrated in the range of 0-1, with an average adhesion score of 3.25. This was significantly different from the model group (P < 0.05), indicating that the STS-GMS / AM-ECM group could reduce the adhesion degree in rats in all three aspects of adhesion grade evaluation and could effectively prevent and treat postoperative peritoneal adhesions in rats.

[0069] Table 10 Adhesion grade scores for each group of rats

[0070] The peritoneal adhesion status of rats in each group is as follows: Figure 25 As shown, in the blank group, no adhesions were found in the peritoneum of the rats, and no adhesions occurred between the cecum and the organs; the adhesion score was 0. In the model group, the cecum adhered directly to the abdominal wall, and the adhesions were strong, requiring sharp separation; this rat had the highest adhesion grade, with an adhesion score of 10. In the drug group, the rat had three adhesions, and these adhesions were vascularized, requiring blunt separation; the adhesion score was 7. In the STS-GMS group, the rat had one adhesion, which was vascularized and embedded, and was strong, requiring blunt separation; the adhesion score was 5. In the STS-GMS / AM-ECM group, gel residue was still visible in the peritoneal cavity, indicating that STS-GMS / AM-ECM has good in vivo retention in the peritoneal cavity. No adhesions were found in the peritoneal cavity of the STS-GMS / AM-ECM group rats, and there were no adhesions between the cecum and the abdominal wall; the adhesion score was 0.

[0071] 4. Observation of the pathological morphology of adhesion tissues After collecting blood from the orbital cavity of rats, they were euthanized by cervical dislocation. Tissue from the cecum and abdominal wall adhesion sites was collected, fixed, embedded, sectioned, and stained with hematoxylin and eosin (HE) for observation. Results are shown below. Figure 26 In the control group, the abdominal and cecal walls of rats were clearly defined, with an intact and tightly packed mesothelial structure. No inflammatory cells or fibroblasts infiltrated the tissues, and no connective tissue hyperplasia was observed. In the model group, the abdominal wall structure was disordered, the mesothelial layer was difficult to identify, adhesions were present, and numerous inflammatory cells and fibroblasts infiltrated the adhesions. The cecal wall also showed extensive inflammatory cell infiltration and connective tissue hyperplasia. The drug solution group was similar to the model group, with a disordered peritoneal structure, indistinguishable mesothelial layer, and still significant inflammatory cell and fibroblast infiltration in the cecal and abdominal walls, although slightly less than in the model group. Connective tissue hyperplasia was also significant, with adhesions forming. The STS-GMS group showed slightly better cecal and abdominal wall structures than the model and drug solution groups, but similarly, the abdominal wall mesothelial layer was disordered, with still a large number of inflammatory cells and fibroblasts infiltrating, and connective tissue hyperplasia was slightly less than in the previous two groups. In the STS-GMS / AM-ECM group, the abdominal wall mesothelial structure was basically repaired and intact, and the mesothelial cells were arranged relatively tightly, similar to the blank group. The cecal serosa surface had been repaired to a certain extent, with a small amount of connective tissue hyperplasia and no adhesion formation, but the cecum still had a certain amount of inflammatory cell infiltration.

[0072] 5. Determination of the expression of adhesion-related factors in rat serum by enzyme-linked immunosorbent assay (ELISA) In the development and progression of peritoneal adhesions, various bioactive factors are involved in the regulation of the disease, and their expression levels also affect the progression of peritoneal adhesions to some extent. In this experiment, the expression of adhesion-related factors in rat serum was measured by enzyme-linked immunosorbent assay (ELISA) to explore the effects of STS-GMS / AM-ECM on related bioactive factors in an adhesion disease model, thereby revealing its preventive and therapeutic effects at the molecular level.

[0073] Blood was collected from the orbital cavity of rats in each group after 7 days. Serum was separated and the expression levels of inflammatory factors (IL-1, TNF-α), fibrinolytic system factors (tPA, PAI-1), and transforming growth factor (TGF-β) were detected by ELISA.

[0074] a) Serum inflammatory factor expression The expression of IL-1β and TNF-α factors in rat serum is as follows: Figure 27 As shown, the serum IL-1β and TNF-α concentrations in the model group were 49.89±1.31 ng / L and 354.37±23.89 ng / L, respectively, which were significantly higher than those in the blank group (P<0.05).

[0075] Compared with the model group, the levels of IL-1β and TNF-α in the drug solution group, STS-GMS group, and STS-GMS / AM-ECM group were significantly decreased (P < 0.05). However, there was no statistically significant difference in the levels of IL-1β and TNF-α between the STS-GMS group and the drug solution group (P > 0.05). Similarly, there was no statistically significant difference in the level of IL-1β between the STS-GMS / AM-ECM group and the drug solution group (P > 0.05). However, the expression level of TNF-α in the STS-GMS / AM-ECM group was statistically significantly different from that in the drug solution group (P < 0.05). These results indicate that STS can effectively reduce the expression levels of serum IL-1β and TNF-α in rats with peritoneal adhesions. The STS-GMS / AM-ECM group still showed a significant anti-inflammatory effect compared with the model group (p < 0.05), indicating that the composite system retains the anti-inflammatory activity of STS while achieving sustained release, and does not affect the prevention and treatment of peritoneal adhesions.

[0076] b) Expression of serum fibrinolytic system-related factors The expression of tPA and PAI-1 factors in rat serum is as follows: Figure 28 As shown, the serum tPA expression level in the model group was significantly lower than that in the blank group (P < 0.05), while the PAI-1 expression level in the model group was significantly higher than that in the blank group (P < 0.05). This indicates that in the rat adhesion model, tPA expression is decreased, PAI-1 expression is increased, the fibrinolytic system is inhibited, leading to the formation of adhesions.

[0077] Compared with the model group, the levels of tPA in the drug solution group, STS-GMS group, and STS-GMS / AM-ECM group were significantly decreased (P < 0.05), while the levels of PAI-1 were significantly increased (P < 0.05). The STS-GMS / AM-ECM group showed statistically significant differences in both tPA and PAI-1 expression levels compared to the drug solution group (P < 0.05). These results indicate that STS can effectively reduce serum tPA levels, increase PAI-1 levels, activate the fibrinolytic system, and inhibit adhesion formation in rats with peritoneal adhesions. Furthermore, the STS-GMS / AM-ECM group further enhanced the activation effect of STS on the fibrinolytic system, thus synergistically inhibiting adhesion formation.

[0078] c) Serum TGF-β expression TGF-β is a key mediator in the process of peritoneal adhesion and fibrosis. It can promote adhesion formation in multiple ways by activating the TGF-β / Smads protein signaling pathway. Figure 29 The results showed that the serum TGF-β expression level in the model group was significantly higher than that in the control group (P < 0.05). Compared with the model group, the expression of TGF-β in the drug solution group, STS-GMS group, and STS-GMS / AM-ECM group was significantly lower (P < 0.05), with the TGF-β expression level in the STS-GMS / AM-ECM group showing a statistically significant difference compared to the drug solution group (P < 0.05). These results indicate that STS can effectively inhibit the expression of serum TGF-β in rats with peritoneal adhesion model and has a certain regulatory effect on the TGF-β / smads protein signaling pathway, thereby inhibiting adhesion formation. The STS-GMS / AM-ECM group further enhanced the downregulation effect of STS on TGF-β, thus having a synergistic effect on the inhibition of adhesion.

[0079] This experiment successfully established a rat peritoneal adhesion model using a physical injury method involving cecal scraping and abdominal wall clamping, and conducted a pharmacodynamic study on the effect of STS-GMS / AM-ECM on postoperative peritoneal adhesion. In the rat adhesion grading score, the average score of STS-GMS / AM-ECM was significantly lower than that of the model group (P < 0.05). Histopathological sections showed that the abdominal wall mesothelial structure in the STS-GMS / AM-ECM group was basically repaired and tightly arranged, similar to the control group, and the cecal serosa surface also showed some degree of repair. The results of adhesion-related factor detection indicated that STS-GMS / AM-ECM significantly enhanced the regulatory effect of STS on tPA, PAI-1, and TGF-β (P < 0.05). All these results indicate that STS-GMS / AM-ECM can effectively prevent and treat rat peritoneal adhesion.

Claims

1. The application of a sodium tanshinone IIA sulfonate microsphere / hydrogel composite drug delivery system in the preparation of drugs for the prevention and / or treatment of peritoneal adhesions after abdominal surgery, characterized in that the composite drug delivery system is injected into the peritoneal cavity in liquid form via laparoscope or syringe, and spontaneously forms a gel state using body temperature to cover the peritoneal wound surface; The composite drug delivery system includes: gelatin microspheres loaded with sodium tanshinone IIA sulfonate, which are composed of genipin-crosslinked gelatin and have sodium tanshinone IIA sulfonate embedded inside. And placental matrix hydrogel; The gelatin microspheres loaded with sodium tanshinone IIA sulfonate are uniformly dispersed within the three-dimensional porous gel network of the placental matrix hydrogel. The preparation method of the composite drug delivery system includes the following steps: 1) Preparation of microspheres encapsulating sodium tanshinone IIA sulfonate: 1.1) Preparation of the aqueous phase: Tanshinone IIA sodium sulfonate was dissolved in water to prepare an STS aqueous solution, which was then mixed with gelatin to swell the gelatin. The mixture was then heated until dissolved to obtain a homogeneous STS-gelatin aqueous solution. in, The mass concentration of the STS aqueous solution is 5~10 mg / mL; The gelatin concentration (w / v) in the STS-gelatin aqueous solution is 14%~18%; 1.2) Preparation of the oil phase: A hydrophobic oil phase was prepared by mixing a nonionic emulsifier with a low hydrophilic-lipophilic balance value of HLB≤6 and preheating it to the emulsification temperature. The hydrophobic oil phase includes one or more of liquid paraffin, vegetable oil, synthetic oil ester, silicone oil, and squalene; The nonionic emulsifier is one or more of Span-80, Span-60, and Span-85; The volume percentage of nonionic emulsifier in the oil phase is 2%; 1.3) Emulsification and cross-linking: Add the aqueous phase obtained in step 1.1) dropwise to the oil phase obtained in step 1.2), and emulsify under stirring conditions to form a water-in-oil emulsion; after emulsification, cool down, add genipin crosslinking agent solution, perform pre-crosslinking and curing under low temperature conditions, and then heat up to room temperature to continue curing; The volume ratio of the aqueous phase to the oil phase is 1:(6~8). The emulsification stirring speed is 200~1500 rpm; The mass concentration of the genipin crosslinking agent solution is 3%~7%; 1.4) Post-processing: After curing, a dehydrating agent is added to the system for dehydration, followed by solid-liquid separation. The oil phase is discarded, and the resulting microspheres are washed alternately with detergent and finally dried to obtain gelatin microspheres encapsulated with STS. 2) Preparation of composite drug delivery system: The gelatin microspheres encapsulated with STS were mixed uniformly with a placental matrix hydrogel precursor solution at a temperature below the gelation temperature, so that the drug-loaded gelatin microspheres were uniformly suspended in the precursor solution, thus obtaining the drug-loaded composite system. The concentration of the placental matrix hydrogel is 8-12 mg / mL, which is a hydrogel prepared by digesting human amniotic membrane-derived decellularized extracellular matrix with pepsin. The placental matrix hydrogel precursor solution is prepared as follows: placental amniotic membrane tissue is decellularized to obtain decellularized placental matrix, which is sterilized by soaking in a double antibiotic solution and washed with PBS. The obtained decellularized placental matrix is ​​digested with pepsin under acidic conditions, and the pH is adjusted to neutral to obtain placental matrix hydrogel precursor solution, which is kept below the gelation temperature for later use.

2. The application according to claim 1, characterized in that, The dehydrating agent includes one or more of anhydrous ethanol, isopropanol, acetone, and n-butanol; The detergent is a combination of non-polar hydrocarbon solvents and polar alcohol solvents, wherein the non-polar hydrocarbon solvents include one or more of petroleum ether, n-hexane, and cyclohexane, and the polar alcohol solvents include anhydrous ethanol or isopropanol dehydrating agents.

3. A sodium tanshinone IIA sulfonate microsphere / hydrogel composite drug delivery system, characterized in that, The composite drug delivery system includes: gelatin microspheres loaded with sodium tanshinone IIA sulfonate, which are composed of genipin-crosslinked gelatin and have sodium tanshinone IIA sulfonate embedded inside. And placental matrix hydrogel; The gelatin microspheres loaded with sodium tanshinone IIA sulfonate are uniformly dispersed within the three-dimensional porous gel network of the placental matrix hydrogel. The preparation method of the composite drug delivery system includes the following steps: 1) Preparation of microspheres encapsulating sodium tanshinone IIA sulfonate: 1.1) Preparation of the aqueous phase: Tanshinone IIA sodium sulfonate was dissolved in water to prepare an STS aqueous solution, which was then mixed with gelatin to swell the gelatin. The mixture was then heated until dissolved to obtain a homogeneous STS-gelatin aqueous solution. in, The mass concentration of the STS aqueous solution is 5~10 mg / mL; The gelatin concentration (w / v) in the STS-gelatin aqueous solution is 14%~18%; 1.2) Preparation of the oil phase: A hydrophobic oil phase was prepared by mixing a nonionic emulsifier with a low hydrophilic-lipophilic balance value of HLB≤6 and preheating it to the emulsification temperature. The hydrophobic oil phase includes one or more of liquid paraffin, vegetable oil, synthetic oil ester, silicone oil, and squalene; The nonionic emulsifier is one or more of Span-80, Span-60, and Span-85; The volume percentage of nonionic emulsifier in the oil phase is 2%; 1.3) Emulsification and cross-linking: Add the aqueous phase obtained in step 1.1) dropwise to the oil phase obtained in step 1.2), and emulsify under stirring conditions to form a water-in-oil emulsion; after emulsification, cool down, add genipin crosslinking agent solution, perform pre-crosslinking and curing under low temperature conditions, and then heat up to room temperature to continue curing; The volume ratio of the aqueous phase to the oil phase is 1:(6~8). The emulsification stirring speed is 200~1500 rpm; The mass concentration of the genipin crosslinking agent solution is 3%~7%; 1.4) Post-processing: After curing, a dehydrating agent is added to the system for dehydration, followed by solid-liquid separation. The oil phase is discarded, and the resulting microspheres are washed alternately with detergent and finally dried to obtain gelatin microspheres encapsulated with STS. 2) Preparation of composite drug delivery system: The gelatin microspheres encapsulated with STS were mixed uniformly with a placental matrix hydrogel precursor solution at a temperature below the gelation temperature, so that the drug-loaded gelatin microspheres were uniformly suspended in the precursor solution, thus obtaining the drug-loaded composite system. The concentration of the placental matrix hydrogel is 8-12 mg / mL, which is a hydrogel prepared by digesting human amniotic membrane-derived decellularized extracellular matrix with pepsin. The placental matrix hydrogel precursor solution is prepared as follows: placental amniotic membrane tissue is decellularized to obtain decellularized placental matrix, which is sterilized by soaking in a double antibiotic solution and washed with PBS. The obtained decellularized placental matrix is ​​digested with pepsin under acidic conditions, and the pH is adjusted to neutral to obtain placental matrix hydrogel precursor solution, which is kept below the gelation temperature for later use.

Citation Information

Patent Citations

  • Preparation method and application of gelatin microspheres

    CN109793717A

  • Composite hydrogel for promoting endometrial regeneration and resisting fibrosis as well as preparation method and application of composite hydrogel

    CN121338117A